In today’s briefing:
- Oura (OURA) IPO: Three Numbers Investors Should Watch
- IPO Rating: ADARx Pharmaceuticals Inc.
- BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients
- Ensign Group’s 71-Facility Expansion — Can Its Turnaround Model Keep Scaling?
- Natera’s $100 Million Early Cancer Detection Bet Opens A Much Bigger Long-Term Market!
- Repligen’s BioLife Deal Targets $20 Million Of Synergies — Can Cell Therapy Accelerate Growth?
- ADARx Pharmaceuticals (ADRX) Seeks $350 Million IPO as AbbVie Deepens Its Bet on siRNA Pipeline
- thoughts on AMT-130 & HD interventions broadly
Oura (OURA) IPO: Three Numbers Investors Should Watch
- Oura, Inc. plans to sell 50.0 million shares at an expected price of $40.00 to $44.00 per share and list on the Nasdaq Global Select Market under the ticker OURA.
- At the $42.00 midpoint, the offering would raise approximately $2.10 billion and value the company at approximately $13.48 billion.
- Goldman Sachs, Morgan Stanley and J.P. Morgan are leading the offering.
IPO Rating: ADARx Pharmaceuticals Inc.
- ADARx Pharmaceuticals presents a high-quality, late-stage biotechnology offering supported by a diversified siRNA platform, a Phase 3 lead program, approximately $427 million of existing cash and investments, and substantial strategic validation from AbbVie.
- The transaction is being led by J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital, providing a strong healthcare-focused underwriting syndicate with broad institutional distribution.
- AbbVie’s planned investment of up to $100 million in a concurrent private placement adds credibility to both the platform and valuation.
BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients
- On September 11, 2026, Biodexa Pharmaceuticals, PLC (BDRX) announced interim results for the first half of 2026 and provided a business update.
- The company is continuing to enroll patients in the registrational SERENTA Phase 3 clinical trial of MTX230 (eRapa) in familial adenomatous polyposis (FAP).
- Thus far, 92 of an expected 168 patients have been enrolled in the study.
Ensign Group’s 71-Facility Expansion — Can Its Turnaround Model Keep Scaling?
- The Ensign Group, Inc. reported financial and operational results for the second quarter of 2026 that reflected continued growth and strong clinical performance across its portfolio.
- The company focuses on post-acute care through a unique integrated clinical model called ONE CLINICAL, which emphasizes collaboration between nursing and therapy disciplines, aiming to improve outcomes such as rehospitalization rates, emergency department visits, and CMS quality ratings.
- Financially, Ensign achieved GAAP diluted earnings per share of $1.68, a 16.7% increase year-over-year, while adjusted earnings per share rose 20.8% to $1.92.
Natera’s $100 Million Early Cancer Detection Bet Opens A Much Bigger Long-Term Market!
- Natera’s second quarter of 2026 results demonstrate continued growth and operational progress across its key business segments: oncology, women’s health, and organ health.
- The company processed a record 1,044,000 tests during the quarter, with clinical Minimal Residual Disease (MRD) oncology tests increasing approximately 56% year-over-year to 283,000 units, including the largest sequential increase recorded at 34,000 units above the prior quarter.
- These volumes contributed to approximately $753 million in revenue, representing a 38% increase compared to Q2 2025, or 40% excluding revenue true-ups.
Repligen’s BioLife Deal Targets $20 Million Of Synergies — Can Cell Therapy Accelerate Growth?
- Repligen reported its financial and operational results for the second quarter of 2026, demonstrating continued growth and strategic progress amid a complex bioprocessing market environment.
- The company achieved $204 million in revenue, reflecting 12% reported growth and 13% organic growth year-over-year, driven primarily by strong recurring revenues across multiple product franchises.
- Proteins led the growth with approximately 50% expansion, supported by contributions from OEM partnerships and growth factor demand.
ADARx Pharmaceuticals (ADRX) Seeks $350 Million IPO as AbbVie Deepens Its Bet on siRNA Pipeline
- ADARx Pharmaceuticals, Inc. (ADRX) is preparing to sell 21.875 million shares of common stock on the Nasdaq Global Select Market at an expected price of $15.00 to $17.00 per share.
- At the $16.00 midpoint, the offering would raise $350.0 million and value the company at approximately $1.64 billion.
- J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital are serving as underwriters.
thoughts on AMT-130 & HD interventions broadly
- SKY-515 came out with 15-month interim data recently.
- What was said in the press release was unsurprising in light of the 12-month data shared.
- At 12 months, participants receiving SKY-0515 demonstrated favorable outcomes across every component of the composite Unified Huntington’s Disease Rating Scale (cUHDRS): Total Functional Capacity (TFC): Mean change from baseline of +0.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
